Childhood Cancer Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Childhood cancer treatment encompasses the full spectrum of oncological therapies used to treat malignancies in children and adolescents from birth to 18 years. Cancer is the leading cause of disease-related death in children aged 5–14 in high-income countries, affecting approximately 300,000 children globally each year. The most common childhood cancers differ fundamentally from adult cancers in biology, treatment response, and survival: leukaemias account for 30–35% of paediatric cancers, brain tumours 20%, lymphomas 10%, neuroblastoma, Wilms tumour, retinoblastoma, bone tumours, and soft tissue sarcomas each comprising 3–8%. Childhood cancers respond dramatically better to treatment than most adult cancers — overall 5-year survival in high-income countries exceeds 80%, compared to approximately 68% for all adult cancers combined. This superior response reflects the rapid cell turnover, chemosensitivity, and greater treatment tolerance of paediatric tumour types, combined with decades of international collaborative trial research (Children's Oncology Group, SIOP, UKCCSG). Treatment is highly protocol-driven and coordinated by multidisciplinary paediatric oncology teams including paediatric oncologists, haematologists, radiation oncologists, paediatric surgeons, pathologists, pharmacists, nurses, social workers, and psychologists. Fertility preservation counselling before potentially gonadotoxic treatment is an important component of comprehensive paediatric oncology care.

Major childhood cancers and their treatment approaches include: Acute lymphoblastic leukaemia (ALL) — the most common childhood cancer; 2–4 years of combination chemotherapy (vincristine, prednisone, asparaginase, methotrexate, 6-mercaptopurine) achieves 90–95% 5-year survival in standard risk; bone marrow transplantation for high-risk and relapsed cases. Acute myeloid leukaemia (AML) — intensive chemotherapy followed by transplantation in many cases; 60–70% 5-year survival. Brain tumours — medulloblastoma (posterior fossa tumour treated with surgical resection, craniospinal radiation, and adjuvant chemotherapy; 70–80% 5-year survival in standard risk); ependymoma; high-grade glioma; low-grade glioma (often managed with surgery alone or temozolomide). Hodgkin and non-Hodgkin lymphoma — chemotherapy with or without radiation; Hodgkin lymphoma has 95%+ 5-year survival. Neuroblastoma — high-risk neuroblastoma requires surgery, intensive chemotherapy, autologous stem cell transplantation, radiation, and anti-GD2 immunotherapy (dinutuximab); overall survival 40–50% for high-risk. Wilms tumour (nephroblastoma) — surgery and chemotherapy; 85–90% 5-year survival. Retinoblastoma — intra-arterial or systemic chemotherapy, laser, cryotherapy, radiation, or enucleation. Osteosarcoma and Ewing sarcoma — neoadjuvant chemotherapy, limb-salvage surgery, and adjuvant chemotherapy.

All children with suspected malignancy require urgent referral to a paediatric oncology centre for comprehensive evaluation and tissue diagnosis. Diagnostic workup includes: clinical examination; blood tests (FBC with differential, LDH, uric acid, liver and renal function, coagulation profile); imaging (CT chest/abdomen/pelvis, MRI for CNS and soft tissue tumours, PET-CT for lymphoma and Ewing sarcoma, bone scan for osteosarcoma); bone marrow biopsy (for leukaemia, lymphoma, neuroblastoma); lumbar puncture for CNS assessment in leukaemia; tumour biopsy with histopathological, immunohistochemical, and molecular (cytogenetics, FISH, NGS) analysis for definitive diagnosis and risk stratification. Modern molecular profiling (whole genome sequencing, RNA sequencing) identifies actionable targets, determines risk group, and guides treatment protocol selection. All children with cancer should ideally be treated at specialised paediatric cancer centres enrolled in national or international clinical trials, where protocol-based treatment achieves the best outcomes. Age, general health, and performance status determine tolerance for intensive chemotherapy regimens, with dose adjustments for infants and younger children. Informed consent with detailed discussion of short-term and long-term toxicities, fertility implications, and life-expectancy is essential.

The survival revolution in childhood cancer is one of medicine's greatest achievements. Overall 5-year survival from childhood cancer in high-income countries has risen from 30% in the 1960s to over 85% in 2024, driven by multimodal protocol chemotherapy, risk-stratified treatment, and advances in supportive care. Specific cancer outcomes: ALL — 90–95% 5-year survival overall; standard-risk ALL approaches 95%; relapsed ALL treated with blinatumomab (CD3/CD19 bispecific antibody) and CAR-T cell therapy achieves remission in 60–80% previously refractory cases. Hodgkin lymphoma — 95%+ 5-year survival with ABVD/BEACOPP chemotherapy. Wilms tumour — 85–90% with surgery and actinomycin D/vincristine. Retinoblastoma — 95%+ survival with modern multimodal therapy; globe salvage rates of 70–80% with intra-arterial chemotherapy. Medulloblastoma — 70–80% standard-risk, 40–60% high-risk. Neuroblastoma (high-risk) — 40–50% with modern anti-GD2 immunotherapy. Long-term survivors (now over 500,000 in the USA alone) require dedicated survivorship care for late effects of treatment including cardiac toxicity (anthracyclines), second malignancies (radiation), endocrine disorders, and neurocognitive impairment.

Chemotherapy side effects include: bone marrow suppression causing anaemia, infections (febrile neutropenia — a medical emergency requiring immediate hospitalisation and broad-spectrum antibiotics), and bleeding; nausea and vomiting (managed with 5-HT3 antagonists, NK-1 antagonists); mucositis; alopecia; nephrotoxicity (cisplatin, ifosfamide); cardiotoxicity (anthracyclines — doxorubicin; lifetime cumulative dose monitoring essential); hepatotoxicity; peripheral neuropathy (vincristine); ototoxicity (cisplatin). Radiation therapy causes site-specific effects: craniospinal radiation impairs neurocognition and growth hormone secretion; pelvic radiation affects fertility; thoracic radiation causes pulmonary fibrosis and cardiac effects. Late effects in cancer survivors (occurring years to decades after treatment) include: secondary malignancies (3–10 times excess risk); cardiac disease (anthracycline cardiomyopathy); endocrine disorders (growth hormone deficiency, hypothyroidism, hypogonadism); neurocognitive impairment (especially after cranial radiation); renal damage; infertility; psychosocial issues. Comprehensive survivorship programmes address these systematically. Targeted therapies and immunotherapy have dramatically reduced chemotherapy burden and toxicity in some cancer types (e.g., imatinib for Ph+ ALL, CAR-T for relapsed ALL).

Childhood cancer treatment in India is available at world-class paediatric oncology centres at a fraction of Western costs. Standard ALL chemotherapy (2–4 years of protocol treatment) costs approximately USD 8,000–25,000 at private hospitals; bone marrow transplantation costs USD 20,000–40,000 — compared to USD 300,000–700,000+ in the USA. Brain tumour surgery plus radiotherapy costs USD 8,000–20,000 in India. Wilms tumour and neuroblastoma treatment (surgery + chemotherapy) costs USD 10,000–30,000. CAR-T cell therapy (tisagenlecleucel/axicabtagene) costs USD 80,000–150,000 in India versus USD 350,000–500,000 in the USA. Leading paediatric oncology centres include: Tata Memorial Hospital Mumbai (India's premier cancer centre), AIIMS Delhi, CMC Vellore, NIMHANS Bangalore, Apollo Cancer Centres, and Narayana Health. Many Indian hospitals are affiliated with international protocols (SIOP, COG). Approximately 40% of childhood cancers in India occur in patients who cannot afford treatment — NGOs and government schemes (Rashtriya Arogya Nidhi) provide financial support. Medical tourism for childhood cancer to India attracts families from Bangladesh, Nepal, Africa, and the Middle East.

Childhood cancer treatment is protocol-driven and multimodal, integrating chemotherapy, surgery, radiation, targeted therapy, and immunotherapy based on tumour type and risk stratification:

• Chemotherapy: The backbone of treatment for leukaemias, lymphomas, and most solid tumours. Protocol-based multi-agent regimens (COG, SIOP protocols) deliver chemotherapy in defined cycles — induction (remission induction), consolidation (eradication of minimal residual disease), and maintenance (low-dose prolonged therapy to prevent relapse). Intrathecal chemotherapy (methotrexate, cytarabine via lumbar puncture) prevents and treats CNS leukaemia. Key agents: vincristine, dexamethasone, asparaginase, anthracyclines (doxorubicin, daunorubicin), cyclophosphamide, methotrexate, etoposide, carboplatin, cisplatin, actinomycin D.
• Surgical resection: Complete excision of primary solid tumours is the single most important prognostic factor. Limb-salvage surgery for osteosarcoma and Ewing sarcoma preserves function. Neoadjuvant chemotherapy shrinks tumours before surgery. Wilms tumour: nephrectomy with sampling of lymph nodes. Neuroblastoma: complete surgical resection correlated with improved survival. Brain tumours: maximal safe resection without neurological deficit.
• Radiation therapy: Craniospinal irradiation for medulloblastoma and ALL with CNS relapse. Involved-field radiation for Hodgkin lymphoma. Local radiation for Ewing sarcoma. Proton beam therapy delivers more precise radiation to paediatric tumours, sparing normal tissues — NICE-approved for specific paediatric CNS tumours in the UK.
• Targeted therapy: Imatinib for Philadelphia chromosome-positive ALL; BRAF inhibitors (dabrafenib) for BRAF-mutant glioma; anti-GD2 immunotherapy (dinutuximab) for high-risk neuroblastoma; crizotinib for ALK-positive ALCL; venetoclax for relapsed AML.
• CAR-T cell therapy: Tisagenlecleucel (Kymriah) — FDA/EMA approved for children with relapsed/refractory B-ALL — achieves complete remission in 65–80% of heavily pretreated patients. Available in India at Tata Memorial Hospital and select Apollo centres.

Structured follow-up is essential during treatment and for lifetime cancer survivorship:

• During treatment: Weekly FBC monitoring — febrile neutropenia (ANC <0.5 × 10^9/L with fever ≥38°C) is a medical emergency requiring immediate hospitalisation and broad-spectrum IV antibiotics. Monthly response assessment with tumour markers, imaging, and bone marrow studies at protocol-defined timepoints. Echocardiogram before and during anthracycline therapy (cumulative dose tracking). Audiometry during cisplatin administration. Renal function during ifosfamide treatment.
• Post-treatment surveillance (5 years): Protocol-specific imaging intervals for relapse detection (PET-CT, CT, MRI). Tumour markers at each visit (AFP, HCG, urinary catecholamines, LDH). Annual bone marrow biopsy for leukaemia survivors in first 2 years.
• Long-term survivorship (lifetime): COG Long-Term Follow-Up Guidelines stratify surveillance by exposures — cardiac monitoring for anthracycline-exposed survivors (echocardiogram every 1–5 years based on dose); annual thyroid function after neck/craniospinal radiation; endocrine panel (GH, LH/FSH, testosterone/oestrogen) after cranial radiation; neurocognitive assessment after CNS-directed therapy; annual secondary malignancy screening in radiation-exposed areas. Fertility counselling; reproductive technology options for those at high risk of gonadal failure.

Protocol-based multimodal therapy is the standard; enrolment in clinical trials and emerging de-escalation strategies offer refinements:

• Clinical trial enrolment: All children with cancer should ideally be treated on or according to current COG, SIOP, or national clinical trial protocols at specialist paediatric oncology centres. Trials continually refine therapy — testing reduced-toxicity regimens for low-risk disease and novel agents for high-risk or relapsed cases. Trial participation provides access to cutting-edge therapies and advances the evidence base for future patients.
• Therapy de-escalation for low-risk disease: Contemporary protocols reduce treatment intensity for low-risk subgroups: low-risk ALL (ETV6-RUNX1-positive, standard risk) requires less intensive chemotherapy with equivalent 5-year survival. Standard-risk Wilms tumour is treated without radiation in current protocols. Low-risk Hodgkin lymphoma achieves cure with 2–4 cycles of chemotherapy and omission of radiation in complete metabolic responders — preserving long-term quality of life.
• Palliative and supportive care: For relapsed or refractory disease beyond curative intent, compassionate use of novel agents (through expanded access programmes) and high-quality paediatric palliative care (pain management, quality of life, psychological support, children's hospice services) represents the appropriate therapeutic focus. Paediatric palliative care teams should be involved from diagnosis for all high-risk cases, not only at end of life.